{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:18:14Z","timestamp":1793409494497,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10787-025-02082-5","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:37:39Z","timestamp":1766021859000},"page":"255-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SARS-CoV-2 infection and gut-lung axis: the potential role of rifaximin"],"prefix":"10.1007","volume":"34","author":[{"given":"Taghreed N.","family":"Almanaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maii A.","family":"Abdelnaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam E.","family":"Abo-ElFetoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"3","key":"2082_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3906\/biy-2005-102","volume":"44","author":"B Aktas","year":"2020","unstructured":"Aktas B, Aslim B (2020) Gut-lung axis and dysbiosis in COVID-19. Turk J Biol 44(3):265\u2013272","journal-title":"Turk J Biol"},{"issue":"2","key":"2082_CR2","doi-asserted-by":"publisher","first-page":"101286","DOI":"10.1016\/j.jksus.2020.101286","volume":"33","author":"MM Al-Ansari","year":"2021","unstructured":"Al-Ansari MM et al (2021) Probiotic lactobacilli: can be a remediating supplement for pandemic COVID-19. a review. J King Saud Univ 33(2):101286","journal-title":"J King Saud Univ"},{"key":"2082_CR3","doi-asserted-by":"publisher","first-page":"174196","DOI":"10.1016\/j.ejphar.2021.174196","volume":"904","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy HM et al (2021a) Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity. Eur J Pharmacol 904:174196","journal-title":"Eur J Pharmacol"},{"key":"2082_CR4","doi-asserted-by":"publisher","first-page":"642822","DOI":"10.3389\/fphar.2021.642822","volume":"12","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy HM et al (2021b) Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives. Front Pharmacol 12:642822","journal-title":"Front Pharmacol"},{"issue":"12","key":"2082_CR5","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1007\/s11033-021-06770-7","volume":"48","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy HM et al (2021c) Niclosamide for covid-19: bridging the gap. Mol Biol Rep 48(12):8195\u20138202","journal-title":"Mol Biol Rep"},{"issue":"11","key":"2082_CR6","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1007\/s11010-021-04232-z","volume":"476","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy HM et al (2021d) The potential role of neopterin in covid-19: a new perspective. Mol Cell Biochem 476(11):4161\u20134166","journal-title":"Mol Cell Biochem"},{"key":"2082_CR7","doi-asserted-by":"publisher","first-page":"649128","DOI":"10.3389\/fnut.2021.649128","volume":"8","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy HM et al (2021e) The Looming Effects of Estrogen in Covid-19: A Rocky Rollout. Front Nutr 8:649128","journal-title":"Front Nutr"},{"key":"2082_CR8","doi-asserted-by":"publisher","first-page":"102008","DOI":"10.1016\/j.pupt.2021.102008","volume":"67","author":"HM Al-Kuraishy","year":"2021","unstructured":"Al-Kuraishy HM et al (2021f) Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects. Pulm Pharmacol Ther 67:102008","journal-title":"Pulm Pharmacol Ther"},{"key":"2082_CR9","doi-asserted-by":"publisher","first-page":"6655380","DOI":"10.1155\/2021\/6655380","volume":"2021","author":"I Allali","year":"2021","unstructured":"Allali I et al (2021) Gut-Lung Axis in COVID-19. Interdiscip Perspect Infect Dis 2021:6655380","journal-title":"Interdiscip Perspect Infect Dis"},{"issue":"11","key":"2082_CR10","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17474124.2021.1991311","volume":"15","author":"S Baradaran Ghavami","year":"2021","unstructured":"Baradaran Ghavami S et al (2021) Cross-talk between immune system and microbiota in COVID-19. Expert Rev Gastroenterol Hepatol 15(11):1281\u20131294","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"2082_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.immuni.2020.01.007","volume":"52","author":"W Barcik","year":"2020","unstructured":"Barcik W et al (2020) The role of lung and gut microbiota in the pathology of asthma. Immunity 52(2):241\u2013255","journal-title":"Immunity"},{"issue":"12","key":"2082_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass NM et al (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12):1071\u20131081","journal-title":"N Engl J Med"},{"key":"2082_CR13","first-page":"e01407","volume":"18","author":"GE Batiha","year":"2022","unstructured":"Batiha GE et al (2022) Common NLRP3 inflammasome inhibitors and Covid-19: divide and conquer. Sci Afr 18:e01407","journal-title":"Sci Afr"},{"issue":"1","key":"2082_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","volume":"157","author":"Y Belkaid","year":"2014","unstructured":"Belkaid Y, Hand TW (2014) Role of the microbiota in immunity and inflammation. Cell 157(1):121\u2013141","journal-title":"Cell"},{"key":"2082_CR15","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.bbih.2021.100257","volume":"14","author":"LD Bobermin","year":"2021","unstructured":"Bobermin LD, Quincozes-Santos A (2021) COVID-19 and hyperammonemia: potential interplay between liver and brain dysfunctions. Brain Behav Immun Health 14:100257","journal-title":"Brain Behav Immun Health"},{"issue":"1","key":"2082_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1128\/AAC.00691-09","volume":"54","author":"EL Brown","year":"2010","unstructured":"Brown EL et al (2010) Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 54(1):388\u2013396","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2082_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/17425255.2018.1488964","volume":"14","author":"E Bruzzese","year":"2018","unstructured":"Bruzzese E et al (2018) Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol 14(7):753\u2013760","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"2082_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrmicro.2016.142","volume":"15","author":"KF Budden","year":"2017","unstructured":"Budden KF et al (2017) Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 15(1):55\u201363","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"2082_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ja.2014.106","volume":"67","author":"F Calanni","year":"2014","unstructured":"Calanni F et al (2014) Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo) 67(9):667\u2013670","journal-title":"J Antibiot (Tokyo)"},{"issue":"3","key":"2082_CR20","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/hep.31708","volume":"74","author":"P Caraceni","year":"2021","unstructured":"Caraceni P et al (2021) The use of rifaximin in patients with cirrhosis. Hepatology 74(3):1660\u20131673","journal-title":"Hepatology"},{"key":"2082_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2021.101611","volume":"75","author":"Y Chen","year":"2021","unstructured":"Chen Y et al (2021) Effect of rifaximin on gut-lung axis in mice infected with influenza A virus. Comp Immunol Microbiol Infect Dis 75:101611","journal-title":"Comp Immunol Microbiol Infect Dis"},{"issue":"1","key":"2082_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1124\/jpet.110.170225","volume":"335","author":"J Cheng","year":"2010","unstructured":"Cheng J et al (2010) Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 335(1):32\u201341","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2082_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.tips.2012.03.003","volume":"33","author":"J Cheng","year":"2012","unstructured":"Cheng J, Shah YM, Gonzalez FJ (2012) Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 33(6):323\u2013330","journal-title":"Trends Pharmacol Sci"},{"key":"2082_CR24","doi-asserted-by":"publisher","first-page":"2340670","DOI":"10.1155\/2020\/2340670","volume":"2020","author":"L Chunxi","year":"2020","unstructured":"Chunxi L et al (2020) The Gut Microbiota and Respiratory Diseases: New Evidence. J Immunol Res 2020:2340670","journal-title":"J Immunol Res"},{"issue":"4","key":"2082_CR25","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41385-019-0160-6","volume":"12","author":"AT Dang","year":"2019","unstructured":"Dang AT, Marsland BJ (2019) Microbes, metabolites, and the gut-lung axis. Mucosal Immunol 12(4):843\u2013850","journal-title":"Mucosal Immunol"},{"issue":"6","key":"2082_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.surge.2012.03.003","volume":"10","author":"EA Deitch","year":"2012","unstructured":"Deitch EA (2012) Gut-origin sepsis: evolution of a concept. Surgeon 10(6):350\u2013356","journal-title":"Surgeon"},{"key":"2082_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2334-10-3","volume":"10","author":"C Dilantika","year":"2010","unstructured":"Dilantika C et al (2010) Influenza virus infection among pediatric patients reporting diarrhea and influenza-like illness. BMC Infect Dis 10:3","journal-title":"BMC Infect Dis"},{"key":"2082_CR28","doi-asserted-by":"publisher","first-page":"110947","DOI":"10.1016\/j.biopha.2020.110947","volume":"133","author":"AU Din","year":"2021","unstructured":"Din AU et al (2021) SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role. Biomed Pharmacother 133:110947","journal-title":"Biomed Pharmacother"},{"issue":"Suppl 1","key":"2082_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/apt.13406","volume":"43","author":"HL DuPont","year":"2016","unstructured":"DuPont HL (2016) Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases. Aliment Pharmacol Ther 43(Suppl 1):1\u20132","journal-title":"Aliment Pharmacol Ther"},{"key":"2082_CR30","doi-asserted-by":"publisher","first-page":"110033","DOI":"10.1016\/j.mehy.2020.110033","volume":"144","author":"MA El-Ghiaty","year":"2020","unstructured":"El-Ghiaty MA, Shoieb SM, El-Kadi AOS (2020) Cytochrome P450-mediated drug interactions in COVID-19 patients: current findings and possible mechanisms. Med Hypotheses 144:110033","journal-title":"Med Hypotheses"},{"key":"2082_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fcimb.2020.00009","volume":"10","author":"R Enaud","year":"2020","unstructured":"Enaud R et al (2020) The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks. Front Cell Infect Microbiol 10:9","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"2082_CR32","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.4049\/jimmunol.1101682","volume":"188","author":"CT Fagundes","year":"2012","unstructured":"Fagundes CT et al (2012) Transient TLR activation restores inflammatory response and ability to control pulmonary bacterial infection in germfree mice. J Immunol 188(3):1411\u20131420","journal-title":"J Immunol"},{"issue":"6","key":"2082_CR33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/HJH.0000000000002468","volume":"38","author":"FJ Fernandez-Fernandez","year":"2020","unstructured":"Fernandez-Fernandez FJ (2020) COVID-19, hypertension and angiotensin receptor-blocking drugs. J Hypertens 38(6):1191","journal-title":"J Hypertens"},{"issue":"4","key":"2082_CR34","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1159\/000068362","volume":"66","author":"S Fiorucci","year":"2002","unstructured":"Fiorucci S et al (2002) Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 66(4):246\u2013256","journal-title":"Digestion"},{"key":"2082_CR35","unstructured":"Gamboa, E., et al., (2020) COVID-19-induced hepatic encephalopathy: A case report. Critical Care & Shock. 23(3):154\u2013157"},{"key":"2082_CR36","first-page":"e504","volume":"3","author":"G Gasbarrini","year":"2021","unstructured":"Gasbarrini G et al (2021) Dysbiosis in the small intestine: towards an optimal therapy to normalize the gut microbiota. Microb Health Dis 3:e504","journal-title":"Microb Health Dis"},{"key":"2082_CR37","doi-asserted-by":"publisher","first-page":"609.1","DOI":"10.1096\/fasebj.2018.32.1_supplement.609.1","volume":"32","author":"GM Hudson","year":"2018","unstructured":"Hudson GM et al (2018) The pregnane X receptor (PXR) modulates NLRP3 inflammasome activation\u2013linking the environment with innate immune signaling. FASEB J 32:609.1-609.1","journal-title":"FASEB J"},{"issue":"13","key":"2082_CR38","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1073\/pnas.1019378108","volume":"108","author":"T Ichinohe","year":"2011","unstructured":"Ichinohe T et al (2011) Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A 108(13):5354\u20135359","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2082_CR39","first-page":"159","volume":"8","author":"N Iorio","year":"2015","unstructured":"Iorio N, Malik Z, Schey R (2015) Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. Clin Exp Gastroenterol 8:159\u2013167","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"2082_CR40","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1038\/s41598-024-54117-6","volume":"14","author":"SF Jorgensen","year":"2024","unstructured":"Jorgensen SF et al (2024) Retraction note: rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency. Sci Rep 14(1):3704","journal-title":"Sci Rep"},{"issue":"3","key":"2082_CR41","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/07391102.2020.1824816","volume":"40","author":"H Kalhor","year":"2022","unstructured":"Kalhor H et al (2022) Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches. J Biomol Struct Dyn 40(3):1299\u20131315","journal-title":"J Biomol Struct Dyn"},{"issue":"8","key":"2082_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.44","volume":"7","author":"DJ Kang","year":"2016","unstructured":"Kang DJ et al (2016) Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition. Clin Transl Gastroenterol 7(8):e187","journal-title":"Clin Transl Gastroenterol"},{"key":"2082_CR43","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1097\/01.hjh.0000500010.38755.52","volume":"34","author":"S Kim","year":"2016","unstructured":"Kim S et al (2016) OS 05\u201310 the microbial metabolite, butyrate attenuates angiotensin II-induced hypertension and dysbiosis. J Hypertens 34:e60\u2013e61","journal-title":"J Hypertens"},{"issue":"5","key":"2082_CR44","doi-asserted-by":"publisher","first-page":"G707","DOI":"10.1152\/ajpgi.00372.2018","volume":"317","author":"R Kitagawa","year":"2019","unstructured":"Kitagawa R et al (2019) Rifaximin prevents ethanol-induced liver injury in obese KK-Ay mice through modulation of small intestinal microbiota signature. Am J Physiol-Gastrointest Liver Physiol 317(5):G707\u2013G715","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"2082_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/diseases9010017","author":"EM Kozlov","year":"2021","unstructured":"Kozlov EM et al (2021) Involvement of oxidative stress and the innate immune system in SARS-CoV-2 infection. Diseases. https:\/\/doi.org\/10.3390\/diseases9010017","journal-title":"Diseases"},{"issue":"7","key":"2082_CR46","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nbt0702-702","volume":"20","author":"C Kruger","year":"2002","unstructured":"Kruger C et al (2002) In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol 20(7):702\u2013706","journal-title":"Nat Biotechnol"},{"key":"2082_CR47","doi-asserted-by":"publisher","first-page":"104936","DOI":"10.1016\/j.phrs.2020.104936","volume":"159","author":"Y Li","year":"2020","unstructured":"Li Y et al (2020) Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome. Pharmacol Res 159:104936","journal-title":"Pharmacol Res"},{"issue":"8","key":"2082_CR48","doi-asserted-by":"publisher","first-page":"816","DOI":"10.7150\/ijms.25543","volume":"15","author":"CC Lu","year":"2018","unstructured":"Lu CC et al (2018) Intestinal dysbiosis activates renal renin-angiotensin system contributing to incipient diabetic nephropathy. Int J Med Sci 15(8):816\u2013822","journal-title":"Int J Med Sci"},{"issue":"12","key":"2082_CR49","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/jac\/dkq345","volume":"65","author":"S Maccaferri","year":"2010","unstructured":"Maccaferri S et al (2010) Rifaximin modulates the colonic microbiota of patients with Crohn\u2019s disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother 65(12):2556\u20132565","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2082_CR50","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000508289","volume":"38","author":"P Malfertheiner","year":"2020","unstructured":"Malfertheiner P, Bornschein J, Ricciardiello L (2020) COVID-19: don\u2019t neglect the gastrointestinal tract! Dig Dis 38(4):259\u2013260","journal-title":"Dig Dis"},{"issue":"23","key":"2082_CR51","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.3748\/wjg.v27.i23.3208","volume":"27","author":"K Megyeri","year":"2021","unstructured":"Megyeri K et al (2021) COVID-19-associated diarrhea. World J Gastroenterol 27(23):3208\u20133222","journal-title":"World J Gastroenterol"},{"key":"2082_CR52","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jff.2014.05.002","volume":"9","author":"F Miremadi","year":"2014","unstructured":"Miremadi F et al (2014) Cholesterol reduction mechanisms and fatty acid composition of cellular membranes of probiotic Lactobacilli and Bifidobacteria. J Funct Foods 9:295\u2013305","journal-title":"J Funct Foods"},{"key":"2082_CR53","doi-asserted-by":"crossref","unstructured":"Monti, P., et al., (2005) The contribution of radiation-induced injury to the gastrointestinal tract in the development of multi-organ dysfunction syndrome or failure. The British Journal of Radiology. 78(Supplement_27): 89\u201394.","DOI":"10.1259\/bjr\/53186341"},{"issue":"5484","key":"2082_CR54","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1126\/science.289.5484.1560","volume":"289","author":"AS Neish","year":"2000","unstructured":"Neish AS et al (2000) Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 289(5484):1560\u20131563","journal-title":"Science"},{"issue":"5","key":"2082_CR55","doi-asserted-by":"publisher","first-page":"766","DOI":"10.14309\/ajg.0000000000000620","volume":"115","author":"L Pan","year":"2020","unstructured":"Pan L et al (2020) Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 115(5):766\u2013773","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2082_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.gastro.2020.07.067","volume":"160","author":"JM Penninger","year":"2021","unstructured":"Penninger JM, Grant MB, Sung JJ (2021) The role of angiotensin converting enzyme 2 in modulating gut microbiota, intestinal inflammation, and coronavirus infection. Gastroenterology 160(1):39\u201346","journal-title":"Gastroenterology"},{"issue":"13","key":"2082_CR57","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.micinf.2013.08.003","volume":"15","author":"T Perlot","year":"2013","unstructured":"Perlot T, Penninger JM (2013) ACE2\u2013from the renin\u2013angiotensin system to gut microbiota and malnutrition. Microbes Infect 15(13):866\u2013873","journal-title":"Microbes Infect"},{"issue":"Suppl 1","key":"2082_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.13437","volume":"43","author":"M Pimentel","year":"2016","unstructured":"Pimentel M (2016) Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 43(Suppl 1):37\u201349","journal-title":"Aliment Pharmacol Ther"},{"key":"2082_CR59","doi-asserted-by":"crossref","unstructured":"Prasad, R., et al., (2019) 48-OR: Gut dysbiosis promotes diabetic retinopathy (DR) through TLR-2 activation by peptidoglycan (PGN) in angiotensin converting enzyme 2 (ACE2) deficient type 1 diabetic (T1D) mice. Diabetes. 68(Supplement_1): p. 48\u2013OR.","DOI":"10.2337\/db19-48-OR"},{"key":"2082_CR60","doi-asserted-by":"publisher","first-page":"1384939","DOI":"10.3389\/fcimb.2024.1384939","volume":"14","author":"ST Raj","year":"2024","unstructured":"Raj ST et al (2024) COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens. Front Cell Infect Microbiol 14:1384939","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"2082_CR61","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41385-020-00361-8","volume":"14","author":"V Sencio","year":"2021","unstructured":"Sencio V, Machado MG, Trottein F (2021) The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes. Mucosal Immunol 14(2):296\u2013304","journal-title":"Mucosal Immunol"},{"issue":"6","key":"2082_CR62","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s10620-021-07155-3","volume":"67","author":"S Sundaram","year":"2022","unstructured":"Sundaram S, Darak H (2022) Functional disease, dysbiosis, and dyspepsia: how helpful is rifaximin? Dig Dis Sci 67(6):1915\u20131916","journal-title":"Dig Dis Sci"},{"key":"2082_CR63","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3389\/fimmu.2019.00611","volume":"10","author":"HX Tan","year":"2019","unstructured":"Tan HX et al (2019) Inducible bronchus-associated lymphoid tissues (iBALT) serve as sites of B cell selection and maturation following influenza infection in mice. Front Immunol 10:611","journal-title":"Front Immunol"},{"key":"2082_CR64","doi-asserted-by":"publisher","first-page":"107272","DOI":"10.1016\/j.intimp.2020.107272","volume":"91","author":"J Tang","year":"2021","unstructured":"Tang J et al (2021) Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4\/NF-kB signaling pathway. Int Immunopharmacol 91:107272","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"2082_CR65","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/infdis\/jiu515","volume":"211","author":"AR Tenorio","year":"2015","unstructured":"Tenorio AR et al (2015) Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy\u2013ACTG A5286. J Infect Dis 211(5):780\u2013790","journal-title":"J Infect Dis"},{"issue":"9","key":"2082_CR66","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.4049\/jimmunol.1101299","volume":"188","author":"AN Thorburn","year":"2012","unstructured":"Thorburn AN et al (2012) Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells. J Immunol 188(9):4611\u20134620","journal-title":"J Immunol"},{"issue":"15","key":"2082_CR67","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S1359-6446(03)02746-6","volume":"8","author":"KM Tuohy","year":"2003","unstructured":"Tuohy KM et al (2003) Using probiotics and prebiotics to improve gut health. Drug Discov Today 8(15):692\u2013700","journal-title":"Drug Discov Today"},{"issue":"5","key":"2082_CR68","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2013.01.005","volume":"34","author":"P van Baarlen","year":"2013","unstructured":"van Baarlen P, Wells JM, Kleerebezem M (2013) Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends Immunol 34(5):208\u2013215","journal-title":"Trends Immunol"},{"issue":"3","key":"2082_CR69","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.micinf.2015.10.008","volume":"18","author":"AT Vieira","year":"2016","unstructured":"Vieira AT et al (2016) Control of Klebsiella pneumoniae pulmonary infection and immunomodulation by oral treatment with the commensal probiotic Bifidobacterium longum 5(1A). Microbes Infect 18(3):180\u2013189","journal-title":"Microbes Infect"},{"key":"2082_CR70","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.12659\/MSM.914538","volume":"25","author":"Y-D Wan","year":"2019","unstructured":"Wan Y-D et al (2019) Improvement of gut microbiota by inhibition of P38 mitogen-activated protein kinase (MAPK) signaling pathway in rats with severe acute pancreatitis. Med Sci Monit: Int Med J Exp Clin Res 25:4609","journal-title":"Med Sci Monit: Int Med J Exp Clin Res"},{"key":"2082_CR71","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.3389\/fimmu.2018.03160","volume":"9","author":"D Wu","year":"2018","unstructured":"Wu D et al (2018) Nutritional modulation of immune function: analysis of evidence, mechanisms, and clinical relevance. Front Immunol 9:3160","journal-title":"Front Immunol"},{"issue":"2","key":"2082_CR72","first-page":"147","volume":"49","author":"K Xu","year":"2020","unstructured":"Xu K et al (2020) Management of COVID-19: the Zhejiang experience Zhejiang Da Xue Xue Bao Yi Xue Ban. J Zhejiang Univ Med Sci 49(2):147\u2013157","journal-title":"J Zhejiang Univ Med Sci"},{"issue":"2","key":"2082_CR73","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","volume":"146","author":"D Xu","year":"2014","unstructured":"Xu D et al (2014) Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 146(2):484\u2013496","journal-title":"Gastroenterology"},{"key":"2082_CR74","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fcimb.2019.00044","volume":"9","author":"L Yang","year":"2019","unstructured":"Yang L et al (2019) Rifaximin alters intestinal microbiota and prevents progression of Ankylosing Spondylitis in mice. Front Cell Infect Microbiol 9:44","journal-title":"Front Cell Infect Microbiol"},{"key":"2082_CR75","doi-asserted-by":"publisher","first-page":"647508","DOI":"10.3389\/fmolb.2021.647508","volume":"8","author":"Y Yang","year":"2021","unstructured":"Yang Y et al (2021) Gastrointestinal microenvironment and the gut-lung axis in the immune responses of severe COVID-19. Front Mol Biosci 8:647508","journal-title":"Front Mol Biosci"},{"key":"2082_CR76","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fmicb.2020.00301","volume":"11","author":"D Zhang","year":"2020","unstructured":"Zhang D et al (2020) The cross-talk between gut microbiota and lungs in common lung diseases. Front Microbiol 11:301","journal-title":"Front Microbiol"},{"issue":"3","key":"2082_CR77","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/cvr\/cvab114","volume":"118","author":"Y Zhang","year":"2022","unstructured":"Zhang Y et al (2022) Gut microbiota dysbiosis promotes age-related atrial fibrillation by lipopolysaccharide and glucose-induced activation of NLRP3-inflammasome. Cardiovasc Res 118(3):785\u2013797","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2082_CR78","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/imm.12896","volume":"154","author":"Q Zhao","year":"2018","unstructured":"Zhao Q, Elson CO (2018) Adaptive immune education by gut microbiota antigens. Immunology 154(1):28\u201337","journal-title":"Immunology"},{"issue":"1","key":"2082_CR79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41421-021-00257-2","volume":"7","author":"H Zhong","year":"2021","unstructured":"Zhong H et al (2021) Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients. Cell Discov 7(1):23","journal-title":"Cell Discov"},{"issue":"4","key":"2082_CR80","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2011.11.013","volume":"56","author":"Q Zhu","year":"2012","unstructured":"Zhu Q et al (2012) Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol 56(4):893\u2013899","journal-title":"J Hepatol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02082-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02082-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02082-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:03:36Z","timestamp":1769706216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02082-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2082"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02082-5","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}